Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients and is marketed in the European Union as a prescription-only antidiabetic agent.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and timely delivery across multiple markets, and ensuring compliance with global quality standards.

Jazeta (sitagliptin) belongs to the DPP-4 inhibitor class used to improve glycemic control in type 2 diabetes.

Type 2 diabetes mellitus: improves blood glucose control when used as part of a comprehensive diabetes management plan.

Sitagliptin may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: mild to moderate head pain. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly indicating inflammation of the pancreas. - Severe allergic reactions: including angioedema, rash or anaphylaxis. - Stevens-Johnson syndrome: life‑threatening skin reaction.

When prescribing Jazeta, clinicians should consider several safety factors. - Renal function: assess kidney function and adjust dose in moderate to severe impairment. - Hepatic function: use with caution in patients with severe liver disease. - History of pancreatitis: avoid or monitor closely for recurrence. - Concomitant insulin or sulfonylureas: increased risk of hypoglycemia; monitor blood glucose. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Sitagliptin can interact with other medicines, requiring attention to potential changes in effect.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): may cause severe hypoglycemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glycemic control; monitor blood glucose. - ACE inhibitors or ARBs: monitor renal function when combined. - Rifampin or other enzyme inducers: may reduce sitagliptin effectiveness.